270 related articles for article (PubMed ID: 32852651)
1. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
2. Etiology and emerging treatments for familial chylomicronemia syndrome.
Spagnuolo CM; Hegele RA
Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
[TBL] [Abstract][Full Text] [Related]
3. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM
Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
[TBL] [Abstract][Full Text] [Related]
4. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.
Hegele RA; Berberich AJ; Ban MR; Wang J; Digenio A; Alexander VJ; D'Erasmo L; Arca M; Jones A; Bruckert E; Stroes ES; Bergeron J; Civeira F; Witztum JL; Gaudet D
J Clin Lipidol; 2018; 12(4):920-927.e4. PubMed ID: 29748148
[TBL] [Abstract][Full Text] [Related]
7. A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome.
Nimonkar AV; Weldon S; Godbout K; Panza D; Hanrahan S; Cubbon R; Xu F; Trauger JW; Gao J; Voznesensky A
J Biol Chem; 2020 Mar; 295(10):2900-2912. PubMed ID: 31645434
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype relationships in patients with type I hyperlipoproteinemia.
Chokshi N; Blumenschein SD; Ahmad Z; Garg A
J Clin Lipidol; 2014; 8(3):287-95. PubMed ID: 24793350
[TBL] [Abstract][Full Text] [Related]
11. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P; Dufour R; Averna M; Arca M; Cefalù AB; Noto D; D'Erasmo L; Di Costanzo A; Marçais C; Alvarez-Sala Walther LA; Banach M; Borén J; Cramb R; Gouni-Berthold I; Hughes E; Johnson C; Pintó X; Reiner Ž; van Lennep JR; Soran H; Stefanutti C; Stroes E; Bruckert E
Atherosclerosis; 2018 Aug; 275():265-272. PubMed ID: 29980054
[TBL] [Abstract][Full Text] [Related]
12. Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene.
Kim KY; Heo YJ; Ko JM; Lee YA; Shin CH; Ki CS; Lee YJ
BMC Endocr Disord; 2024 Apr; 24(1):47. PubMed ID: 38622573
[TBL] [Abstract][Full Text] [Related]
13. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.
Baass A; Paquette M; Bernard S; Hegele RA
J Intern Med; 2020 Apr; 287(4):340-348. PubMed ID: 31840878
[TBL] [Abstract][Full Text] [Related]
14. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
[TBL] [Abstract][Full Text] [Related]
15. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
16. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
17. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
18. Incidental finding of severe hypertriglyceridemia in children. Role of multiple rare variants in genes affecting plasma triglyceride.
Buonuomo PS; Rabacchi C; Macchiaiolo M; Trenti C; Fasano T; Tarugi P; Bartuli A; Bertolini S; Calandra S
J Clin Lipidol; 2017; 11(6):1329-1337.e3. PubMed ID: 28951076
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic algorithm for familial chylomicronemia syndrome.
Stroes E; Moulin P; Parhofer KG; Rebours V; Löhr JM; Averna M
Atheroscler Suppl; 2017 Jan; 23():1-7. PubMed ID: 27998715
[TBL] [Abstract][Full Text] [Related]
20. Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome.
Marco-Benedí V; Lamiquiz-Moneo I; Álvarez-Sala LA; Civeira F
Atherosclerosis; 2018 Aug; 275():342-345. PubMed ID: 30015297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
